Clinical trials: HV
Cachexia
Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)
The aim of this early phase two-part study was to compare the bioavailability (BA) pharmacokinetics (PK) and pharmacodynamics (PD) of racemic pindolol with the benzoate salt of the S-enantiomer of pindolol (ACM-001.1) and provide…
- Trial name
- NCT06028321
- Testing
- Part 1 Group 1 Regime A (ACM-001.1), Part 1 Group 2 Regimen C (Pindolol), Part 2 Group D (Pindolol)
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Actimed Therapeutics Ltd
Pulmonary Disease, Chronic Obstructive
GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)
Batefenterol (BAT) is a novel bifunctional molecule that combines muscarinic antagonism and beta2-agonism in a single molecule and is in development for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02666287
- Testing
- BAT/FF, BAT, FF
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.
1. To evaluate the diagnostic performance of [18F]-APN-1607 injection PET imaging in detecting uptake patterns consistent with AD neuropathological changes as defined by the National Institute on Aging-Alzheimer's Association…
- Trial name
- NCT07752784
- Testing
- [18F]-APN-1607
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Healthy, NAFLD
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
The primary objective of this study is to evaluate the effect of itraconazole, a strong inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A, CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of…
- Trial name
- NCT04845646
- Testing
- ASC41, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Healthy Volunteers, Asthma
Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals
RP3128 is a calcium release activated calcium (CRAC) channel modulator. The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending dose(s) of RP3128 in healthy…
- Trial name
- NCT02958982
- Testing
- RP3128
- Where
- Canada
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Rhizen Pharmaceuticals SA
Hypoglycemia
Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207
The trial is a single-centre, randomized, double-blind, phase 1b trial of multiple ascending doses of ZP4207 administered s.c. to healthy volunteers (HV) to evaluate the safety, tolerability, pharmakocinetic (PK) and…
- Trial name
- NCT02390141
- Testing
- ZP4207
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Healthy Volunteers (HV)
Phase I Study of HXN6005 in Adult Healthy Participants
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamics of HXN6005 in Healthy Participants.
- Trial name
- NCT07449741
- Testing
- HXN6005
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
HV
A Phase 1 Clinical Study in Healthy Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-41012 in Healthy Participants
- Trial name
- NCT07584876
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
Healthy Volunteers (HV)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KR25102 in Healthy Volunteers
Phase 1 Single Ascending Doses(SAD): Six cohorts of 53 healthy volunteers (HVs) will receive a single IV bolus injection of study drug or placebo.
- Trial name
- NCT07618156
- Testing
- KR25102 for Injection
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Healthy Volunteers (HV)
Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects
A phase 1, randomized, double-blind, parallel group, single-dose study to compare the pharmacokinetics, safety and immunogenicity of two formulations of Omalizumab (Process-Changed CMAB007 and Xolair) in healthy subjects.
- Trial name
- NCT07246252
- Testing
- Process-Changed CMAB007, Xolair (omalizumab)
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Healthy Volunteers
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers
The primary objective of the study is to evaluate the safety and tolerability of single doses of REGN9933 in healthy participants The secondary objectives of the study are to: Evaluate the effects of single doses of REGN9933 on…
- Trial name
- NCT05102136
- Testing
- REGN9933
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
[18F]APN-1607 PET in Subjects With AD Compared to HC
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT05542953
- Testing
- [18F]APN-1607
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics
HIV Infections
DDI HV (ATV - Merck)
The purpose of this study is to to assess the effect of ATV 300 mg BID on the PK of raltegravir 400 mg BID, to assess the effect of raltegravir 400 mg BID on the PK of ATV 300 mg BID, and to assess the ECG effects of ATV 300 mg…
- Trial name
- NCT00518297
- Testing
- Raltegravir, Atazanavir, Atazanavir + Raltegravir
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Covid19
Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients
This first-in-human clinical study is a Phase 1a/ 1b, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and PK/PD of NTR-441 in healthy subjects and patients with COVID-19 after single…
- Trial name
- NCT04941183
- Testing
- NTR-441
- Where
- 4 sites in Austria, Ukraine
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Neutrolis
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)
This study is designed to investigate the safety, tolerability and pharmacokinetics of inhaled CHF 6001 after single and multiple doses in healthy volunteers.
- Trial name
- NCT01703052
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy Adult Participants, Diabetic Kidney Disease
Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439…
- Trial name
- NCT07473323
- Testing
- MTX-439
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Mediar Therapeutics
Healthy Volunteers (HV), Healthy Volunteer
A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants
This study aims to find out how much adimanebart gets into the blood circulation of healthy adults. Researchers will measure the amount of adimanebart in blood over time to learn how it moves through the body.
- Trial name
- NCT07673601
- Testing
- Adimanebart IV, Adimanebart SC - formulation A, Adimanebart SC - formulation B
- Where
- Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- argenx
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)
The purpose of this study is to evaluate the potential for cardiac repolarization, according to electrocardiographic monitoring (including QT and QTc intervals), of two dose levels of CHF5993 pMDI (beclomethasone…
- Trial name
- NCT05830071
- Testing
- CHF5993, CHF5259, Moxifloxacin 400mg
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy Volunteers (HV)
A Study of IBI3042 in Healthy Adult Participants
This is a randomized, investigator- and participant-blinded, placebo-controlled, parallel-group, dose-escalation Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of IBI3042…
- Trial name
- NCT07842393
- Testing
- Investigational Drug: IBI3042
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fortvita Biologics (USA)Inc.
Hepatitis C
A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects
This is a First in Human study of orally administered CDI-31244, a non-nucleoside inhibitor (NNI) in healthy volunteers and HCV infected individuals
- Trial name
- NCT02760758
- Testing
- CDI-31244
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Cocrystal Pharma, Inc.